메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

메디트, 프로그레시브 오소돈틱스 인수에 발맞춰 글로벌 교정 사업부 출범

글로벌 디지털 덴티스트리 선도 기업으로서 독자 기술력과 세계 최고 수준 임상 교육 플랫폼 결합해 교정 사업 확대 나서 한국 서울 및 캘리포니아 앨리소비에호, 2026년 5월 8일 -- 글로벌 디지털 덴티스트리 솔루션 분야를 선도하는 기업 선도기업 메디트(Medit Corp.)가 글로벌 교정 사업부(Global Orthodontic Business Division)를 신설하고 미국 자회사 메디트 USA(Medit USA Inc.)를 통해 캘리포니아주 앨리소비에호에 본사를 둔 교정 전문 교육기관 프로그레시브 오소돈틱스(Progressive Orthodontics)를 인수했다고 5월 7일 발표했다. 이번 인수는 메디트가 교정 분야로 추진 중인 전략적 확장 가운데 가장 중요한 행보로 평가되고 있으며 자사의 디지털 스캐닝 및 소프트웨어 역량을 세계적으로 인정받는 임상 교육 플랫폼과 통합하는 데 의의가 있다. "이번 인수와 글로벌 교정 사업부 출범은 메디트에 중대한 전환점이다. 당사는 단순히 교정 시장에 진입하는 데 그치지 않고 그 시장 자체를 재편하고자 한다. 프로그레시브 오소돈틱스는 오랜 임상 전문성과
- 김갑성 기자
- 2026-05-08 21:55
AAVnerGene Announces AAVone®2.1, a Next-Generation Sing…

ROCKVILLE, Md., May 8, 2026 -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® single-plasmid AAV production system, designed to improve AAV vector productivity, full-capsid yield, manufacturing efficiency, and cost effectiveness. AAVone®2.1 has achieved ~1x1016 genome copies (GC)/L of cell culture and greater than 70% full capsids at harvest, representing a significant advance over AAVone®1.0 and conventional multi-plasmid AAV production systems, which often generate high proportions of e
- 김갑성 기자
- 2026-05-08 20:26
The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combi…

CHENGDU, China, May 8, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. The application is for sac-TMT in combination with MSD's[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[2]) as first‑line treatment for adult patients wit
- 김갑성 기자
- 2026-05-08 19:29
What Sets Medtec China Apart from Other Medical Device Manu…

SHANGHAI, May 8, 2026 -- Building a successful medical device requires precise engineering, reliable materials, and a resilient supply chain. Finding the right partners to bring your vision to life is a major challenge. The Medtec China trade show solves this problem. As a leading medical device development expo, it stands as a premier gathering dedicated entirely to medical device research, design, and manufacturing. This highly anticipated event runs from September 1-3, 2026, at the Shanghai New International Expo Center (Halls N1-N4). You can secure your free early bird pass by regi
- 김갑성 기자
- 2026-05-08 19:21
TOOTOO Self-Develops Ultra-Olaflur, Achieving a New Breakthrou…

Acid erosion resistance increased by 5 times, remineralization effect 1.7 times higher than previous generation Olaflur HANGZHOU, China, May 8, 2026 -- Recently, Chinese children's age-specific wash and care brand TOOTOO (a brand under Hangzhou Daoyu Xingqing Biotechnology Co., Ltd.) has achieved a major scientific research breakthrough in the field of children's oral care. The company's three-year self-developed Ultra-Olaflur has reached a purity of over 98%, achieving a comprehensive upgrade in anti-cavity performance. This achievement marks a key technological breakthrough for Chi
- 김갑성 기자
- 2026-05-08 18:21
BioQ Debuts at in‑cosmetics Global, Showcasing China's A…

PARIS, May 8, 2026 -- BioQ, the biotechnology affiliate of Chinese skincare brand GUYU, made its first appearance as a raw-material supplier at in-cosmetics Global, held April 14–16, 2026, in Paris. Widely regarded as the most prestigious stage for cosmetic ingredients, the event admits only companies with proven independent R&D and production capabilities — placing BioQ alongside established giants. BioQ Senior Scientist Hou Sen presented three proprietary ingredients — demonstrating GUYU's capacity to independently develop and produce all its key raw materials. AuroGlab i
- 김갑성 기자
- 2026-05-08 17:34
The 23rd World Congress on Breast Cancer and Breast Heal…

TIANJIN, China, May 8, 2026 -- To further promote academic exchange and practical collaboration in the global field of breast health, and to advance the standardized prevention and treatment of breast cancer, the 23rd World Congress on Breast Cancer and Breast Healthcare will be held in Tianjin, China, from May 8–10, 2026. The congress is jointly organized by the World Society for Breast Health and the China Anti-Cancer Association, and co-organized by Tianjin Medical University Cancer Institute & Hospital, Tianjin Breast Cancer Prevention and Treatment Center, and the National Cli
- 김갑성 기자
- 2026-05-08 17:06
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004…

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 8, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for HBM7004, enabling the initiation of a first-in-human (FIH) Phase I clinical trial. The study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HB
- 김갑성 기자
- 2026-05-08 17:02
Rznomics Announces U.S. FDA Regenerative Medicine Advan…

RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, with trans-splicing ribozyme-based RNA editing platform SEOUL, South Korea, May 8, 2026 -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation to RZ-001, its lead investigational candidate for the treatment of hepatocellular carcinoma (HCC). RMAT designation is a specialized FD
- 김갑성 기자
- 2026-05-08 16:17
Men can step up to domestic duties to help arrest the glob…

BEIJING, May 8, 2026 -- A more active role for men in fatherhood and domestic chores could be the key lever of population rebound to arrest collapsing fertility rates around the world. Men being more hands-on in infant care and household responsibilities can support family building with evidence that it may also improve their personal well-being and professional fulfillment. Speaking at the 2026 Congress of the Asia Pacific Initiative on Reproduction, renowned reproductive endocrinologist Professor Dominique de Ziegler said the world was facing a general co
- 김갑성 기자
- 2026-05-08 12:03

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-05-09_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 05월 09일 23시 50분